Relutrigine, a novel sodium channel modulator, is under FDA Priority Review for the treatment of pediatric SCN2A and SCN8A epileptic encephalopathies.

FDA assigned PDUFA target action date of September 27, 2026BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: ...

Praxis Precision Medicines reported that its EMBOLD trial of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies was stopped early for efficacy, while also confirming FDA ...

Embold Health Launches Embold Edge, The First National Quality-Driven Health Plan Designed to Reduce Waste and Lower Total Cost of Care Embold Edge Enables Employers and Health Plans to Launch an ...

Morgan Health has unveiled its next investment, joining the latest funding round for Embold Health, a physician-led data analytics company. The healthcare arm of JPMorgan Chase will chip in $5 million ...

Expanded clinical insights, responsible AI and deeper ecosystem integrations define a milestone year Embold Health is completing a transformative year defined by measurable employer impact, expanded ...

Organizations are looking for ways to reduce the cost of care without sacrificing the quality of care for their workforce. Nashville-based Embold Health is working to set the standard in physician ...

DUBLIN, Ohio & NASHVILLE, Tenn.--(BUSINESS WIRE)--Quantum Health (“Quantum”), the creator of healthcare navigation, has signed a definitive agreement to acquire Embold Health (“Embold”), a leading ...

Embold Edge Enables Employers and Health Plans to Launch an Alternative, Quality-Driven Health Plan Without Network or Carrier Disruption For years, employers and health plans have relied on price ...